384 related articles for article (PubMed ID: 34453155)
21. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.
Duijvesz D; Burnum-Johnson KE; Gritsenko MA; Hoogland AM; Vredenbregt-van den Berg MS; Willemsen R; Luider T; Paša-Tolić L; Jenster G
PLoS One; 2013; 8(12):e82589. PubMed ID: 24391718
[TBL] [Abstract][Full Text] [Related]
22. Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.
Worst TS; von Hardenberg J; Gross JC; Erben P; Schnölzer M; Hausser I; Bugert P; Michel MS; Boutros M
Mol Cell Proteomics; 2017 Jun; 16(6):998-1008. PubMed ID: 28396511
[TBL] [Abstract][Full Text] [Related]
23. Protein signatures to distinguish aggressive from indolent prostate cancer.
Garcia-Marques F; Liu S; Totten SM; Bermudez A; Tanimoto C; Hsu EC; Nolley R; Hembree A; Stoyanova T; Brooks JD; Pitteri SJ
Prostate; 2022 Apr; 82(5):605-616. PubMed ID: 35098564
[TBL] [Abstract][Full Text] [Related]
24. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
[TBL] [Abstract][Full Text] [Related]
25. Proteomics in prostate cancer biomarker discovery.
Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
[TBL] [Abstract][Full Text] [Related]
26. Recent progress and perspectives on prostate cancer biomarkers.
Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer proteomics.
Masters JR
OMICS; 2011 Mar; 15(3):169-71. PubMed ID: 21319990
[TBL] [Abstract][Full Text] [Related]
28. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
29. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
30. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
31. Mass spectrometry-based expression profiling of clinical prostate cancer.
Wright ME; Han DK; Aebersold R
Mol Cell Proteomics; 2005 Apr; 4(4):545-54. PubMed ID: 15695425
[TBL] [Abstract][Full Text] [Related]
32. Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for protein markers with potential clinical utility.
Garbis SD; Townsend PA
Expert Rev Proteomics; 2013 Aug; 10(4):337-54. PubMed ID: 23992417
[TBL] [Abstract][Full Text] [Related]
33. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
34. Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation.
Wang L; Skotland T; Berge V; Sandvig K; Llorente A
Eur J Pharm Sci; 2017 Feb; 98():80-85. PubMed ID: 27664330
[TBL] [Abstract][Full Text] [Related]
35. Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.
Barnett CL; Tomlins SA; Underwood DJ; Wei JT; Morgan TM; Montie JE; Denton BT
Med Decis Making; 2017 Oct; 37(7):815-826. PubMed ID: 28363265
[TBL] [Abstract][Full Text] [Related]
36. Beyond PSA: the next generation of prostate cancer biomarkers.
Prensner JR; Rubin MA; Wei JT; Chinnaiyan AM
Sci Transl Med; 2012 Mar; 4(127):127rv3. PubMed ID: 22461644
[TBL] [Abstract][Full Text] [Related]
37. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
[TBL] [Abstract][Full Text] [Related]
38. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Kohaar I; Petrovics G; Srivastava S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013716
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
40. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
